A carregar...
FDG-PET is a good biomarker of both early response and acquired resistance in BRAF(V600) mutant melanomas treated with vemurafenib and the MEK inhibitor GDC-0973
BACKGROUND: The BRAF inhibitor, vemurafenib, has recently been approved for the treatment of metastatic melanoma in patients harboring BRAF(V600) mutations. Currently, dual BRAF and MEK inhibition are ongoing in clinical trials with the goal of overcoming the acquired resistance that has unfortunate...
Na minha lista:
| Main Authors: | , , , , , , |
|---|---|
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
Springer
2012
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3405466/ https://ncbi.nlm.nih.gov/pubmed/22651703 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/2191-219X-2-22 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|